Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2474635 | Acta Pharmaceutica Sinica B | 2011 | 6 Pages |
Renal fibrogenesis is related to the development of diabetic nephropathy. TGF-β receptor II (TGF-β RII) plays a vital role during renal fibrogenesis by phosphorylation and activation of type I receptors and downstream regulators. Nicousamide is a 1.1 class of drug, which can inhibit renal fibrosis in animal models of diabetic nephropathy. After cloning and purification of TGF-β RII, an in vitro substrate phosphorylation assay was set up to investigate the ability of nicousamide to inhibit phosphorylation and formation of cellular downstream proteins. Our results validate nicousamide as a potent inhibitor of phosphorylation of TGF-β RII.
Graphical abstractAn in vitro substrate phosphorylation assay was set up to investigate the ability of nicousamide to inhibit phosphorylation and formation of cellular downstream proteins and validate nicousamide as a potent inhibitor of phosphorylation of TGF-β RII.Figure optionsDownload full-size imageDownload as PowerPoint slide